GLP1R and type 2 diabetes mellitus: In subjects with T2DM, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and/or glucagon-like peptide 1-receptor agonists (GLP-1RA) are recommended in addition to standard therapy (antihypertensive drugs, statins, antithrombotic therapy etc.)to reduce cardiovascular risk, regardless of glycemic control.